Related references
Note: Only part of the references are listed.Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections
Andrea L. H. Kwa et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2008)
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Alexandre Prehn Zavascki et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates
Roxanne J. Owen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
The future should not look like the past
[Anonymous]
LANCET INFECTIOUS DISEASES (2006)
Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
AC Gales et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Old Polymyxins are back: Is resistance close?
Jian Li et al.
CLINICAL INFECTIOUS DISEASES (2006)
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Jian Li et al.
LANCET INFECTIOUS DISEASES (2006)
Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration
J Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa
VH Tam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City -: A new threat to our antibiotic armamentarium
S Bratu et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections
ME Falagas et al.
CLINICAL INFECTIOUS DISEASES (2005)
Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use
M Al-Aloul et al.
PEDIATRIC PULMONOLOGY (2005)
Evaluation of colistin as an agent against multi-resistant in Gram-negative bacteria
J Li et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate
J Li et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
The need for new antibiotics
DM Livermore
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration
J Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin:: A comparison with imipenem-susceptible VAP
J Garnacho-Montero et al.
CLINICAL INFECTIOUS DISEASES (2003)
Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis
J Li et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Dry powder inhalation of antibiotics in cystic fibrosis therapy:: part 2 Inhalation of a novel colistin dry powder formulation:: a feasibility study in healthy volunteers and patients
PPH Le Brun et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2002)
Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock
P De Paepe et al.
CLINICAL PHARMACOKINETICS (2002)
The pharmacokinetics of colistin in patients with cystic fibrosis
MD Reed et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
J Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
